TG Therapeutics raises annual revenue outlook to about US$1B

A higher annual sales target puts revenue near US$1 billion as TG Therapeutics, Inc. NASDAQTGTX raised its outlook on Monday alongside its third-quarter results. The new global forecast adds roughly US$50 million to the company's previous target for 2026.

TG now expects U.S. Briumvi net product revenue of approximately US$915 million to US$920 million for 2026. Its previous forecast was US$890 million to US$905 million, so the increase reaches the domestic business as well as the global total.

TG is a commercial-stage biotechnology company focused on B-cell diseases, with an approved multiple sclerosis medicine sold in the United States and through an overseas licensing partner.

Third-quarter global revenue reached US$259.9 million, while quarterly net income was US$55.5 million, according to the Nov. 9 results. TG expects pivotal results for subcutaneous Briumvi around year-end or early 2027, bringing a development milestone alongside the higher commercial forecast.

Shares closed at US$59.83 on Nasdaq at 4 p.m. EST on Nov. 6, according to NASDAQTGTX, before Monday's results were released.

Briumvi Sales Carry The Higher Forecast

U.S. Briumvi net product revenue reached US$232.6 million in the quarter ended Sept. 30, approximately 52 per cent above the same period a year earlier. Domestic sales account for most of TG's product revenue, making the higher U.S. forecast a measure of the medicine's commercial expansion.

Total quarterly net product revenue rose to US$240 million from US$159.3 million a year earlier, according to the Nov. 9 release. That category includes sales to TG's overseas licensing partner, rather than only U.S. prescriptions.

License, milestone, royalty and other revenue contributed another US$19.9 million during the third quarter. Within that category, royalties were US$4.1 million, while license, milestone and other revenue accounted for US$15.8 million.

The distinction separates the recurring product-sales business from revenue recognized under the overseas commercialization agreement. The approximately US$1 billion global target therefore covers more than domestic Briumvi sales.

"With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI," TG chairman and chief executive Michael S. Weiss said in the release.

TG kept its 2026 operating expense target at approximately US$450 million to US$500 million. That measure covers research and development and selling, general and administrative expenses excluding non-cash compensation, including subcutaneous manufacturing and secondary manufacturer start-up costs.

Read more: Xeris Biopharma raises sales outlook after US$107.2M quarter

Research and development expense increased to approximately US$51.3 million in the third quarter from US$40.9 million a year earlier. TG attributed the increase to subcutaneous manufacturing, secondary manufacturer expenses and clinical development costs in its Nov. 9 results.

The company also repurchased approximately US$100 million of shares during the third quarter of 2026. Cumulative repurchases through Sept. 30 reached US$300 million, representing approximately 6 per cent of shares outstanding across its repurchase programs.

Read more: Moderna reports US$162M quarterly profit and raises sales outlook

Dosing Programs Approach A Readout

TG's development plans would broaden how Briumvi is administered beyond its existing intravenous business. The company described a potential simplified intravenous initiation launch in mid-2027 and a potential subcutaneous launch in 2028; those remain prospective milestones.

The quarterly subcutaneous regimen is being evaluated in a fully enrolled Phase 3 trial, according to the Nov. 9 update. The next scheduled discussion is TG's results call at 8:30 a.m. EST on Nov. 9, followed by the expected year-end or early-2027 readout testing that dosing approach.